|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||31.34 - 31.50|
|52-week range||19.76 - 34.39|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||130.58|
|Forward dividend & yield||0.24 (0.74%)|
|Ex-dividend date||30 Mar 2023|
|1y target est||N/A|
The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.
An analyst had a fresh new take on the company's prospects, and it wasn't all that positive.
Shares in the Anglo-Swedish drugs giant fell 0.4% in afternoon trade in London.